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BRAIN SPECT IMAGING IN HUNTINGTONS
DISEASE BEFORE AND AFTER THERAPY WITH OLANZAPINE
CASE REPORT
ELBA C. S. C. ETCHEBEHERE*, MARIANA C. L. LIMA*,
WALMIR PASSOS**, JAIME A MACIEL JR***,
ALLAN O. SANTOS*, CELSO DARÍO RAMOS*, EDWALDO E. CAMARGO****
ABSTRACT - Olanzapine, an atypical antipsychotic drug, was administered to a patient with Huntington’s
disease (HD) with marked choreiform movements. Brain SPECT with 99mTc-HMPAO was performed before and
after treatment. Brain SPECT imaging has been performed in patients with HD in order to determine the status of
basal ganglia perfusion. The use of brain SPECT with 99mTc-HMPAO before and after treatment in patients with
HD has not been yet reported. The marked hypoperfusion of the basal ganglia on brain SPECT performed before
therapy with olanzapine improved significantly after treatment.
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SPECT cerebral na doença de Huntington antes e após terapia com olanzapina: relato de caso
RESUMO - Olanzapina, um antipsicótico atípico, foi administrada a uma paciente com doença de Huntington
(DH) com acentuados movimentos coreicos. O SPECT cerebral com HMPAO-99mTc foi realizado antes da  paciente
iniciar qualquer tratamento e após tratamento com olanzapina. O SPECT cerebral tem sido realizado em pacientes
com DH para avaliar a perfusão dos núcleos da base. O uso do SPECT cerebral com HMPAO-99mTc antes e após
terapia em pacientes com DH ainda não foi relatado. A acentuada hipoperfusão observada nos núcleos da base na
imagem de SPECT cerebral, obtida antes da terapia com olanzapina, melhorou de forma significativa após o
tratamento.
PALAVRAS CHAVE: doença de Huntington, SPECT cerebral, olanzapina, núcleos da base,
HMPAO-99mTc.
Huntington’s disease (HD) is a hereditary degenerative disease characterized by movement
disorders, personality and psychiatric changes and dementia. Histopathologically there is neuronal
and neuroreceptor loss in the striatum. The use of brain SPECT imaging to evaluate basal ganglia
(BG) perfusion in patients with HD is well established because it has been recognized that the
functional changes precede the morphological changes. Abnormalities such as bilateral hypoperfusion
of the BG have been described, as well as cortical hypoperfusion in severely ill patients. The use of
brain SPECT imaging with 99mTc-HMPAO for treatment evaluation in patients with HD has not been
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reported. The purpose of this study is to evaluate the status of BG perfusion with 99mTc-HMPAO in
a patient with HD before and after treatment with olanzapine.
CASE REPORT
A 34 year-old female patient with a strong family history of Huntington’s disease began with choreiform
movements at the age 29 and progressive loss of memory at the age 32. Prior to therapy the patient was submitted
to brain SPECT imaging with 99mTc-HMPAO that revealed marked hypoperfusion of the left basal ganglia (BG).
Semi-quantification of the BG, using the cerebellum as a reference, revealed: right BG = 0.91; left BG = 0.66
(normal = 0.97±0.07, using a control group of 50 normal volunteers; 25 females, 25 males, ages ranging from 19
to 44 years, mean 26.6 years).
Treatment with haloperidol resulted in very little improvement of her symptoms. A new brain SPECT
imaging with 99mTc-HMPAO performed 2 years after the beginning of treatment with haloperidol revealed only
slight improvement of the perfusion of the left BG. Semi-quantification of the BG, on this occasion, using the
cerebellum as a reference, revealed: right BG = 0.90; left BG = 0.81 (normal = 0.97±0.07).
The patient was then hospitalized, haloperidol was discontinued and treatment with 10 mg of olanzapine
per day was begun. Five days later the choreiform movements had improved markedly. A brain SPECT with
99mTc-HMPAO performed 20 days after the beginning of treatment with olanzapine revealed marked improvement
of the perfusion of the left BG (Fig 1). Semi-quantification of the BG, using the cerebellum as a reference
revealed: right BG = 0.91; left BG = 0.92 (normal = 0.97±0.07). The semi-quantification as well as the visual
analysis demonstrated clearly an improvement of the perfusion of the BG, when compared to the study prior to
treatment.
DISCUSSION
Huntington’s disease is characterized by neuronal loss and neuroreceptor changes in the
striatum, including a reduction of dopamine receptor density. There are many reports using brain
SPECT imaging that describe BG hypoperfusion in patients with HD. These abnormalities are
described, in general, as bilateral hypoperfusion of the BG, normally involving the head of the
caudate, reflecting reduction of neuronal function1-5, but hypoperfusion of the frontal6 and parietal
lobes have been described in severely ill HD patients.
Olanzapine, an atypical antipsychotic drug, is a potent dopamine antagonist that reduces D
2
occupancy in the BG. Olanzapine also binds to many serotonin receptor subtypes with greater affinity
for dopamine receptors, α
1
-adrenergic receptors, histaminergic H
1 
receptors
 
and muscarinic receptors.
Olanzapine has less affinity than haloperidol for D
2
 eceptors. Brain SPECT studies with 123I-IBZM
have demonstrated a higher uptake of this tracer in patients treated with olanzapine than in those
treated with haloperidol, therefore reflecting lower levels of D
2 
occupancy7 by olanzapine when
compared to haloperidol.
The beneficial action of these drugs is due to the blockage of the D
2
 receptors of the striatum
neurons that project to the external globus pallidus. The activity of these neurons, already impaired
by HD, would be inhibited by the nigro-striatum dopaminergic afferent fibers. The therapeutic effect
would be linked to D
2
 receptor blockage which would increase the activity in the external globus
pallidus-striatal pathway and improve the choreiform movements. Therefore, a greater therapeutic
improvement with olanzapine would not be expected when compared to haloperidol, since olanzapine
has less affinity for D
2
 receptors. Thus, the therapeutic effect of olanzapine may not be related to the
blockage of D
2
 receptors. On the other hand, an improvement in perfusion of the BG, associated to
an improvement in symptoms, suggests a possible beneficial effect of olanzapine on the metabolism
of these neurons.
This patient has demonstrated that although neuronal loss and neuroreceptor changes occur
in HD patients, there is probably a population of neurons that remain intact and capable of response
to treatment. This was clearly demonstrated by the marked difference of 99mTc-HMPAO uptake by
the BG before and after olanzapine therapy.
865Arq Neuropsiquiatr 1999;57(3-B)
Fig 1. Brain SPECT imaging with 99mTc-HMPAO in a patient with Huntington’s
disease and severe choreiform movements. (A) Before treatment, there is marked
hypoperfusion of the left basal ganglia. (B) After 2 years of treatment with
haloperidol there is only slight improvement of the left basal ganglia perfusion.
(C) After withdrawal of haloperidol and a 20-day trial with olanzapine there is
marked improvement of left basal ganglia perfusion.
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In conclusion, the improvement of BG perfusion with olanzapine in patients with HD is not
simple to explain by the proposed mechanism of action of olanzapine. D
2
 r ceptors are already
reduced in number in these patients and non-functioning and olanzapine is preferentially a D
2
antagonist. These facts suggest that there may be another mechanism, perhaps not related to D
2
receptors, by which olanzapine acts on the BG and improves their perfusion. The use of 99mTc-
HMPAO brain SPECT imaging before and after therapy in patients with HD may help to better
understand the pathophysiology of this disease and the mechanism of action of these drugs.
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